PSA density vs. PSA level and the prediction of prostate cancer risk

A newly published study in the journal Urology (the “Gold Journal”) has suggested that — at least for patients with a PSA level between 4 and 10 ng/ml — PSA density may be better than PSA level in the determination of which of these patients need to go on to have a biopsy.

  • PSA density was a much more accurate predictor of risk than PSA alone for all men with a PSA level of 4 ng/ml or higher.
  • Among men with a PSA level of < 4 ng/ml, PSA density was no better than PSA at predicting actual prostate cancer (of any type or of clinical significance).


Genomic Testing in Cancer Treatment

Genomic testing is done on cancerous tissue taken from the prostate in order to provide information about how your prostate cancer might behave. By looking at the genetic makeup of the cancer, these tests may help predict whether your prostate cancer grows slowly or aggressively.

Genomic testing can be performed on both biopsy tissue and on tissue from an entire prostate following a prostatectomy.

Read more on Zero